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A B S T R A C T
We assessed the coronary heart disease (CHD) risk in 130 HIV-infected patients with no major past cardiovascular
event treated with combination antiretroviral therapy (CART) between May 2004 and June 2005. We also investigated
the association of HIV disease parameters (CD4+ T-cell counts, HIV viral load, AIDS diagnosis, antiretroviral medica-
tions and lipodystrophy), demographics, anthropometrics, clinical features, smoking status, dyslipidemia, adherence to
the Mediterranean diet, and the metabolic syndrome (MS) to the Framingham risk score. The median 10-year CHD risk
was 6.4% (IQR 3.3–13.0) for males and 1.8% (IQR 1.0–6.7) for females. The CHD risk was ³10% in 31.1% (32 of 103)
males and in 14.8% (4 of 27) females. MS was present in 27 (20.8%) individuals. Participants who met the definition of
the MS had a 2.63 times greater chance of having a CHD risk ³10% (95% CI, 1.09–6.39; p=0.032). On multivariable
analysis, we found that a CHD risk ³10% was associated with: a lowest ever CD4+ T-cell counts of less than 50 per
microliter and a past history of AIDS (OR, 6.26; 95% CI, 1.61–24.36; p=0.008); alcohol consumption ³10 g/day (OR,
3.87; 95% CI, 1.56–14.22; p=0.041); and age ³43 years (OR, 1.30; 95% CI, 1.17–1.45; p<0.001). Interventions to reduce
the modifiable cardiovascular risk are needed in Croatian patients treated with CART.
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Introduction
Combination antiretroviral therapy (CART) can cause
wide spectrum of metabolic abnormalities, dyslipidemia
and lipodystrophy (peripheral fat loss and/or visceral
obesity)1,2. The metabolic changes include hypercholes-
terolemia, hypertriglyceridemia, insulin resistance, im-
paired glucose tolerance and type 2 diabetes2,3. On the
other hand, it has been recognized for almost 25 year
that elevated levels of total and low-density lipoprotein
(LDL) cholesterol constitute a main risk factor for coro-
nary heart disease (CHD)4. The Framingham equation re-
presents a useful tool for calculation the CHD risk, cardio-
vascular disease or myocardial infarction (MI) risk during
the next 5 or 10 years5. Assessment of the metabolic syn-
drome (MS) also provides an accessible diagnostic tool to
aid identification of participants with an increased CHD
risk6. Current guidelines recommended that the risk of
cardiovascular disease in HIV-infected patients be esti-
mated from conventional risk-prediction model, such as
the Framingham score, which combines different risk
factors into numeric estimate of absolute risk7.
The purposes of the present study were to estimate the
prevalence and risk factors associated with the predicted
10 year CHD in participants without an established car-
diovascular event. We also examined the association of
HIV disease parameters (CD4+ T-cell counts, HIV viral
load, and AIDS diagnosis), antiretroviral medications,
lipodystrophy, adherence to the Mediterranean diet and
the presence of the MS to the Framingham risk score.
Patients and Methods
Study design
We enrolled 130 participants for this analysis, from
the study on the effect of the Mediterranean diet on body
shape changes and dyslipidemia during CART conducted
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on 136 participants from May 2004 to June 20058,9. Parti-
cipants were under follow-up at the Outpatient HIV/AIDS
Department at the University Hospital of Infectious Dis-
eases in Zagreb that provides medical care to the total
HIV/AIDS population in Croatia10. The study protocol
was approved by the institutional review boards of Uni-
versity Hospital of Infectious Diseases in Zagreb.
We included in the study participants older than 18
years, documented HIV-1 seropositive status, had re-
ceived CART for at least one year, and had lipid measure-
ments. We excluded 6 participants because they already
had experienced a cardiovascular event (two of them had
myocardial infarction, and four of them had transient ce-
rebral ischemic attack).
Examination protocol
We administered a standard questionnaire to collect
demographic data, smoking, and adherence to the anti-
retroviral treatment. Participants came in the morning
having fasted overnight, as recommended in clinical prac-
tice. A physical examination and medical history was
performed by a physician. Body-shape changes classified
in the »lipoatrophy« or »lipohypertrophy« group have
been described earlier8. Measurements of weight (in kilo-
grams), height (in centimeters) were performed in all
participants. Body mass index (BMI) calculated as weight
in kilograms divided by the square of height in meters.
Participants were defined as normal weight (18.5–24.9),
overweight (25.0–29.9) or obese (³30.0). We dichotomiz-
ed BMI of our participants into a value zero for partici-
pants below 25 and into those equal or above 25. Waist
circumference (in cm) was determined using a measuring
tape positioned at the point of iliac crest and umbilicus.
Blood pressure was measured in the left arm with the el-
bow flexed to heart level using a mercury sphygmoma-
nometer. Demographic data were collected in a struc-
tured interview. Smoking status was classified into two
categories, never or past and current. Histories of myo-
cardial infarction, transient cerebral ischemic attack,
treatment for hypertension, diabetes type 2, and dyslipi-
demia were obtained based on interview questions.
Dietary assessment and energy expenditure
The block of 150-item of semi-quantitative food-fre-
quency questionnaire provided by Antonia Trichopolou11,
and translated into Croatian, was used to estimate usual
adherence to the Mediterranean diet8,9. A scale of 0 to 9
was derived11, and we dichotomized the Mediterranean
diet score into below the median (<4 points, indicating
low adherence) and at or above the median (³4 points, in-
dicating moderate to high adherence to the Mediterra-
nean diet).
The seven-item of International Physical activity Qu-
estionnaire translated into Croatian and used to assess
energy expenditure12.
Definition of metabolic syndrome
We used the International Diabetes federation (IDF)
definition of the MS13,14. Briefly, the MS is present when
central obesity defined by a waist circumference >94 cm
for Europid men, and >80 cm for Europid women is pres-
ent, plus any two of following four components: raised
triglyceride level ³1.7 mmol/L, or specific treatment of
this lipid abnormality; reduced HDL-cholesterol level
<1.0 mmol/L for men and <1.3 mmol/L for women, or
specific treatment of this lipid abnormality; raised sys-
tolic blood pressure ³130 mm Hg or diastolic blood pres-
sure ³85 mm Hg, or treatment previously diagnosed hy-
pertension; raised fasting plasma glucose ³5.6 mmol/L,
or previously diagnosed type 2 diabetes.
Coronary heart disease risk assessment
We assessed the 10-year CHD risk using algorithm de-
rived from Framingham study5. We used Framingham
tools from Copenhagen HIV programme15 that uses algo-
rithms developed and published by Anderson et al.16. The
variables included in the calculation of 10-year CHD risk
are: gender, current age in years, cigarette smoking, dia-
betes mellitus, left ventricular hypertrophy, systolic blood
pressure, total cholesterol and high-density lipoprotein
(HDL)-cholesterol. Predicted risk of CHD was classified
as moderate to high when it was at ³10% in the next
10-years.
Biologic measures
We directly measured fasting plasma glucose, total
cholesterol, HDL-cholesterol, LDL-cholesterol and tri-
glycerides by standard enzymatic techniques on Olym-
pus AU400. Viral load was obtained by polymerase chain
reaction, using the Amplicor Monitor RT-PCR assay (Ro-
che Molecular Systems) with lower limit detection of 50
or 400 copies/mL. We performed CD4 lymphocyte counts
by flow cytometry.
Antiretroviral treatments
We recorded three categories of antiretroviral drug
combinations (CART): currently receiving a non-nucleo-
side reverse-transcriptase inhibitor (NNRTI) based CART,
a protease inhibitor (PI) combination or using both. We
also recorded the use of each antiretroviral drug, and du-
ration of administration.
Statistical analysis
We expressed our data with frequencies for categori-
cal variables, median, and interquartile ranges for quan-
titative variables. The calculated 10-year CHD risk was
dichotomized at ³10% and used in bivariable and multi-
variable analysis. We used the Wilcoxon-Mann-Whitney
test for comparisons of non-normally distributed quanti-
tative variables. For comparison of the categorical vari-
ables we used Fisher exact tests, c2-tests or odds ratios
(OR) with 95% confidence intervals (CI). We included
into the multivariable logistic regression analysis HIV
disease factors significantly associated with a moder-
ate-to high CVD risk (nadir CD4 cell count, history of
AIDS, viral load). Also included were other variables
found significant in bivariable analysis. Except for age
other components of the Framingham equation (sex,
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smoking, hypertension, cholesterol and HDL) were not
included into the multivariable analysis. In this analysis,
we dichotomized the age of our participants at the me-
dian (43 years). The final model included HIV disease
variables and other non-HIV disease variables which
suggested an association with the outcome. The analyses
were done using SAS version 9.1.3 software (SAS insti-
tute INC, Cary, North Carolina, USA) and the level of sig-
nificance was at the 0.05 level.
Results
Participant characteristics
The median age of 130 participants was 43.0 (IQR,
36–49) years. The median 10-year Framingham predict-
ed CHD score was 5.6% (IQR, 2.5–11.0). It was 6.4%
(IQR, 3.3–13.0) for males and 1.8% (IQR, 1.0–6.7) for fe-
males. Thirty-six (28%) participants had a 10-year CHD
risk of ³10%, and 5 (4%) participants had 10-year CHD
risk higher than 25%.
Forty-three percent acquired HIV through heterosex-
ual sex, 40% through sex between men and 10% through
injecting drugs 2% from blood products and in 5% the
route of infection was unknown.
Sixty-five (50%) of participants were current smok-
ers. Moderate alcohol consumption (10 to 30 g/day) was
reported by 31 (24%) and heavy alcohol consumption
(³30 g/day) was reported by 18 (14%).
Metabolic syndrome
Among 130 HIV infected participants (males: 103,
79%), there were 27 (21%) participants who reached the
condition-specific cut points for MS. MS was found more
frequently in females (10/27, 37%) then in males (17/103,
17%; p=0.031). We found that 78 (60%) of HIV-infected
participants had a normal body mass index (BMI: <25),
42 (32%) were overweight (BMI: ³25), and 10 (8%) were
obese (BMI: ³30). The prevalence of high blood pressure
>130 mmHg) was 56 (43%) and >140 mm Hg in 13
(10%) of participants. Abdominal obesity was found in 42
(32%) participants. Females were more frequently to
have abdominal obesity (14/27, 52%) than males (28/103,
27%; p=0.021). The prevalence of elevated blood glucose
>6 mmol/L was 12 (9%).
Non-HIV-related factors associated
with CHD risk.
We dichotomized the 10-year CHD risk at ³10% and
selected clinical features and laboratory measurements
are presented in Table 1 and 2. Abdominal obesity defin-
ed by waist circumference measurements and by hip cir-
cumference measurements were weakly correlated to the
10-year CHD risk (r=0.34; p<.001 and r=0.25; p=0.004,
respectively). In bivariable analysis, a significant differ-
ence between participants with a high 10-year CHD risk
at ³10% compared with those with low 10-year CHD risk
at <10% was observed for BMI ³25.0 (OR 3.35; 95% CI,
0.41–8.82; p=0.003), hypertension (systolic blood pressure
³140 mm Hg, and or diastolic blood pressure ³90 mm Hg;
OR 8.98; 95% CI, 3.73–21.61; p<0.001), total cholesterol
>5.0 mmol/L (OR 5.23; 95% CI, 1.87–14.61; p=0.002),
ethanol drinking ³10 g/days (OR 2.77; 95% CI, 1.26–6.13;
p=0.012). Participants who met the definition of the MS
had a 2.63 times greater chance of having a CHD risk
³10% (95% CI, 1.09–6.39; p=0.032).
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TABLE 1
COMPARISON OF 10-YEAR CORONARY HEART DISEASE RISK AND DIFFERENT CHARACTERISTICS OF 130 HIV INFECTED
PARTICIPANTS (INTERVAL VARIABLES)







Age, years 39 (34–45) 54 (49–60) <0.001
Body mass index, kg/m2 23.5 (21.3–26) 25.6 (24–27.6) 0.005
Waist circumference, cm 87 (81–92) 90 (85.5–97.5) 0.003
Hip circumference, cm 91 (86–95) 94 (90–99.5) 0.008
Systolic blood pressure, mm Hg 120 (110–130) 130 (120–145) <0.001
Diastolic blood pressure, mm Hg 75 (70–80) 90 (80–90) <0.001
Total cholesterol, mmol/L 5.3 (4.6–6.0) 6.4 (5.7–7.0) <0.001
HDL-cholesterol, mmol/L 1.2 (1.0–1.5) 1.1 (1.0–1.3) 0.173
LDL-cholesterol, mmol/L 3.5 (3.0–3.9) 4.0 (3.4–4.6) 0.013
Trigliceridi, mmol/L 2.1 (1.4–3.0) 2.3 (1.8–4.9) 0.025
Glucose, mmol/L 4.8 (4.4–5.3) 5.3 (4.8–5.8) 0.002
Log plasma HIV RNA 5.5 (5.0–5.8) 5.8 (5.4–6.0) 0.030
Duration of HIV infection, years 5.3 (2.2–8.3) 6.1 (4.1–8.3) 0.375
Duration of treatment, years 3.0 (2.0–5.0) 5.0 (2.5–6.0 0.004
*Values are medians and interquartile ranges
An overall estimate for blood pressure ³130 mm Hg
was 43 (42%) in men and 13 (48%) in women, for total
cholesterol greater than 5 mmol/L was 63 (61%) in men
and 19 (70%) in women, and for BMI ³25 was 42 (41%) in
men and 10 (37%) in women. Adherence to the Mediter-
ranean diet, energy expenditure ³8.6 MET-h/days, con-
sumption of olive oil, current smoking, and family his-
tory of CHD were not associated with the dichotomized
CHD risk score.
HIV-related factors associated with CHD
Using bivariable analysis (Table 2), we identified HIV-
related factors associated with 10-year CHD risk ³10%:
history of AIDS diagnosis (OR 2.85; 95% CI, 1.28–6.33;
p=0.010); higher viral load (OR 2.71; 95% CI, 1.18–6.25;
p=0.019) and CD4 count <50 per mm3 (OR 2.91; 95% CI,
1.32–6.42; p=0.008).
A lower mean HDL-cholesterol we found in participants
who had a CD4 count 50 (mean 1.2±0.4 mmol/L vs. mean
1.3±0.3 mmol/L; p=0.047). A higher mean total cholesterol
was found in participants who had lipohypertrophy (mean
6.0±1.2 mmol/L vs. mean 5.5±1.2 mmol/L; p=0.020).
Combination antiretroviral treatment
Fifty-eight participants (45%) used currently a PI,
and 72 (55%) used currently NNRTI CART. There was no
association with the type of CART and a higher risk
10-year CHD. Higher mean total cholesterol was found
in participants treated with PI-based compared to non-
-PI-based CART (mean 5.8±1.2 mmol/L vs. mean 5.2±1.2
mmol/L; p=0.031). In participants, who had received
nevirapine we observed a higher 10-year CHD risk at
³10% (OR 2.90; 95% CI, 1.11–7.60; p=0.030) compared
to non-nevirapine regimens, while exposure to the other
antiretroviral medications was not associated with a
higher 10-year CHD risk at ³10%.
Multivariable analysis
In multivariable analysis (Table 3), participants who
had an age ³43 years, a CD4 count less than 50 per
microliter plus history of AIDS diagnosis, as well as alco-
hol consumption ³10 g/day were more likely to have a
10-year CHD risk ³10%. Overweight or obese partici-
pants increased the likelihood of CDH risk, but the dif-
ference was not significant.
Discussion
We found that more than one quarter of our partici-
pants had a 10-year CHD risk of ³10%. This finding cor-
responds with a previous Italian report in which a 10-year
CHD risk of ³10% was found in 22% of HIV infected par-
ticipants, and a 10-year CHD risk above 20% was found
in 6% of participants17. In our study, the median CHD
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TABLE 2
COMPARISON OF 10-YEAR CORONARY HEART DISEASE RISK AND DIFFERENT CHARACTERISTICS OF 130 HIV INFECTED
PARTICIPANTS (CATEGORICAL VARIABLES)
10-year risk coronary heart disease 10%
Characteristics
10-y-CHD <10% 10-y-CHD 10%
OR 95% CI p
n=94 (72%) n=36 (28%)
Male gender (yes versus no) 71 76% 32 89% 0.39 0.12–1.21 0.102
Hypertension* (yes versus no) 14 15% 22 61% 8.98 3.73–21.61 <0.001
Body mass index 25 (yes versus no) 30 32% 22 61% 3.35 1.51–7.45 0.003
Alcohol consumption 10 g/day (yes versus no) 19 53% 27 29% 2.77 1.26–6.13 0.012
Metabolic syndrome (yes versus no) 15 16% 12 33% 2.63 1.09–6.39 0.032
CD4 <50 per mL (yes versus no) 33 35% 22 61% 2.91 1.32–6.42 0.008
AIDS diagnosis (yes versus no) 36 38% 23 64% 2.85 1.28–6.33 0.01
Viral load peak >300 000 copies/mL(yes versus no) 46 49% 26 72% 2.71 1.18–6.25 0.019
Lipoatrophy (yes versus no) 35 37% 17 47% 1.51 0.69–3.28 0.3
Lipohypertrophy (yes versus no) 26 28% 16 44% 2.09 0.94–4.65 0.07
Lipodystrpophy (yes versus no) 47 50% 23 64% 1.77 0.80–3.90 0.158
Pretreated with
Protease inhibitors (yes versus no) 66 70% 30 83% 2.12 0.80–5.66 0.133
Non-nucleoside analogues (yes versus no) 60 64% 28 78% 1.98 0.81–4.84 0.132
Currently treated with
Protease inhibitors (yes versus no) 43 46% 15 42% 0.85 0.39–1.84 0.676
Non-nucleoside analogues (yes versus no) 49 52% 23 64% 1.63 0.74–3.59 0.229
*Hypertension was defined as raised systolic blood pressure 140 mm Hg and or diastolic blood pressure 90 mm Hg, or treatment of
previously diagnosed hypertension
risk was 6.4% (mean age 44 years) for man and 1.8 (mean
age 41.4 years) for woman. This is similar or less com-
pared to findings from Germany, Norway or USA. In a
German cohort the median of 10-year CHD risk was esti-
mated to be 9% in HIV infected men (mean age, 43 years)
and 2% in HIV infected women (mean age 37 years)18. In a
cohort from Oslo the mean 10-year CHD risk was 9%
(about 80% men, mean age 41 years)19, and in a large
American multicentre study the median CHD risk was 6%
(mean age 46 years) in HIV infected man and 2% (mean
age 42 years) in HIV infected woman20. In the study by De
Socio et al.17 the average 10-year CHD risk was 7% in HIV
infected participants. In addition, the estimated CHD risk
was higher in HIV infected participants treated with
CART compared to age matched group of HIV uninfected
participants of the general population17,21.
We identified a number of factors related to the 10-
year CHD risk of ³10%: older age, higher BMI, waist cir-
cumference, hip circumference, hypertension and total
cholesterol. These findings are expected and consistent
with prior evidence that conventional risk factors such as
smoking, hypertension, total cholesterol, decreased HDL-
-cholesterol, increased triglycerides, diabetes and family
history were all significantly associated with MI in HIV-
-infected participants22.
Based on the calculation of BMI we estimated that
32% of HIV-infected participants were overweight, and
8% of them were obese. Jacobson et al reported that 35%
of HIV infected participants were overweight and 18%
were obese in the USA23. Of note, we found that 41% of
HIV-infected men and 37% of woman were overweight or
obese based on a BMI ³25. This is in agreement with re-
cent study for men, but we found twice less women met
criteria for being overweight. We found that participants
with higher BMI have a three times higher 10-year CHD
risks of ³10% (Table 2).
Our results suggest that the total cholesterol is a stron-
ger predictor of CHD risk than LDL-cholesterol. Others
found that total cholesterol and LDL-cholesterol are simi-
lar in their ability to predict initial CHD events5. Higher
waist circumference was associated with a greater 10-year
CHD risk. Waist circumference is not primarily driven by
the inclusion of 10-year CHD risk in the definition.
Our results showed that alcohol consumption is asso-
ciated with a higher 10-year CHD risk. This is in contrast
with a recent study in which participants who had ³14
drinks per week compared by abstainers had signifi-
cantly decreased predicted CHD20. However, this has
been explained by selection bias; individuals at highest
cardiac risk were more likely to receive physician advice
to curtail their alcohol consumption, or early death of
heavy drinkers at highest CHD risk20. We found that 50%
of participants were current smokers which contributed
significantly to a higher CHD risk.
The prevalence of MS was 21% in Croatian HIV-in-
fected participants which is similar to 27% found in Dan-
ish HIV-infected patients24. A recent French study found
a lower prevalence of MS (7.4%) in HIV infected men25,
and 5.9% in HIV uninfected French men26. A study from
the UK found the prevalence of MS of 10%27. The preva-
lence of MS was 24% in HIV positive participants in the
greater Boston area or Rhode Island23. The estimated
prevalence of MS was 17% in HIV-infected participants
from Barcelona and increased to 27% for those aged
50–59 years28. In a large international study the preva-
lence of MS in HIV-infected participants was 14–18%29.
In an Italian study MS was in 22% of HIV infected parti-
cipants30. In addition the prevalence of MS was higher in
HIV infected participants treated with CART compared
to group of HIV uninfected participants of the general
population31. The MS was highly predictive for develop-
ment of diabetes29,32, as well as increased risk of cardio-
vascular events6,33. We found that female participants
were somewhat more likely to have MS, but the statisti-
cal difference was not significant.
A consistent finding in our analysis was a strong asso-
ciation between lower CD4 T-cell counts and higher
10-year CHD risk. Others have also reported that a lower
CD4 T-lymphocyte count is associated with a higher car-
diovascular risk34,30. The duration and severity of im-
munosuppresion in HIV infected individuals might be a
risk factor for ischemic cardiovascular diseases34. In ad-
dition Escaut et al. observed that MI was associated with
a lower mean CD4 T-cell count in HIV-infected individu-
als compared with those without MI35. Lower CD4 T-lym-
phocyte counts might also be risk factor, even the marker
for MI34. AIDS diagnosis was associated with a higher
CHD and this is also consistent with findings from a US
multicentric analysis20. It may reflect adverse metabolic
changes among those with advanced disease36. However,
using multivariable analysis in our study only partici-
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TABLE 3.
MULTIVARIABLE ANALYSIS OF FACTORS RELATED TO MODERATE TO HIGH CORONARY HEART DISEASE RISK AMONG
130 HIV INFECTED PATIENTS
Variable OR 95% CI p
Age 43 years 1.30 1.17–1.45 <0.001
Alcohol consumption 10 g/day 3.87 1.56–14.22 0.041
BMI overweight or obese 3.01 0.88–10.27 0.079
CD4 <50 per mL and AIDS diagnosis 6.26 1.61–24.36 0.008
Viral load peak >300 000 copies/mL 1.30 0.36–4.77 0.691
* Moderate CHD risk was defined as 10-year risk 10%
pants with both an AIDS history and with a nadir CD4
cell of less than 50 per microliter had a 10-year CHD risk
³10%. We did not find an association between the 10-year
CHD risks and PI-based or NNRTI-based treatment.
This study has several limitations. The sample size is
relatively small, and the design of this study was cross-
sectional, so generalizations of these finding should be
made with caution. Biases are inherent in observational
studies, for example the association of nevirapine use
and 10-year CHD ³10% was observed in our study be-
cause nevirapine has a favorable lipid profile and thus we
used it when the CHD risk was high. Nevertheless the
main finding that a low nadir CD4 cells count and a his-
tory of AIDS is associated with a higher CHD risk is in
concordance with findings from larger studies.
In conclusion, as survival of HIV infected participants
increases37 cardiovascular complications are becoming
more important. We found that a significant number of
HIV infected participants have a moderate to high CHD
risk which needs to be addressed in routine care. Ad-
vanced HIV disease can also be associated with a higher
CHD risk, hence earlier treatment and diagnosis of HIV-
-infection is important. In Croatia up to 35% of partici-
pants presented to care with AIDS in recent years38. Al-
though the Mediterranean diet is associated with longev-
ity we did not find an association between adherence to
the diet and lower CHD risk calculated by the Fra-
mingham equation.
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PREDVI\ANJE RIZIKA KORONARNE BOLESTI SRCA U SUDIONIKA ZARA@ENIH HIV-OM
IZ HRVATSKE LIJE^ENIH CART-OM
S A @ E T A K
Procijenili smo rizik koronarne bolesti (KB) u 130 sudionika zara`enih HIV-om, lije~enih kombinacijom antiretro-
virusnih lijekova (CART) koji nisu ranije imali ve}a kardiovaskularna o{te}enja od svibnja 2004 do lipnja 2005. Tako|er
smo istra`ili povezanosti parametara HIV bolesti (broj CD4+ T stanica, stupanj HIV-viremije, AIDS dijagnoza, antire-
trovirusni lijekovi, lipodistrofija) demografske, antropometrijske, klini~ke odlike, pu{a~ki status, dislipidemiju, pridr`a-
vanje mediteranskoj prehrani i metaboli~ki sindrom (MS) u odnosu na ra~unanje Framingham-ovog rizika. Medijan
desetgodi{njeg rizika KB je 6,4% (IQR 3,3–13,0) za mu{ke i 1,8% (IQR 1,0–6,7) za `enske. Rizik od KB ³10% je 31,1%
(32 od 103) u mu{kih i 14,8% (4 od 27) u `enskih. MS je bio prisutan u 27 (20,8%) pojedinaca. Sudionici sa MS imali su
2,63 puta ve}u {ansu imati rizik KB ³10% (95% CI 1,09–6,39; p=0,032). U multivarijatnoj analizi na{li smo da }e ispi-
tanici imati rizik KB ³10%: ako su ikad imali broj CD4+ T-stanica manje od 50 po mikrolitru i AIDS definiraju}u bolest
u anamnezi (OR 6,26; 95% CI 1,61–24,36; p=0.008); konzumirali alkohol ³10 g/dnevno (OR, 3,87; 95% CI 1,56–14,22;
p=0,041); i bili u dobi ³43 godine (OR, 1,30; 95% CI 1,17–1,45; p<0,001). Potrebne su intervencije koje smanjuju pro-
mjenjive kardiovaskularne rizike u hrvatskih bolesnika koji se lije~e CART-om.
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